Growth through acquisitions Leverage the company’s recent acquisitions of Affinity Biologicals and George King Bio-Medical to cross-sell coagulation antibodies, diagnostic products, and integrated test kits to existing customers and distribution partners, expanding portfolio and market reach.

Global expansion Target international distributors and laboratories in regions where CRYOcheck and Factor IX/Factor VIII assays have market authorization, capitalizing on recent EU/UK approvals and ongoing regulatory expansions to grow overseas sales.

Hemostasis innovation Position CRYOcheck Chromogenic assays and bovine Factor VIII as differentiators for labs adapting to new hemophilia therapies (e.g., FVIII mimetics and extended half-life products), offering compatibility testing and assay updates.

Clinical lab partnerships Deepen relationships with clinical laboratories through direct overnight delivery capabilities, field support, and education on hemostasis diagnostics to drive adoption of new assays and complementary antibodies from Affinity Biologicals.

Strategic collaborations Explore partnerships with larger distributors or funding channels (as seen with Procuritas Partners) to scale marketing reach, expand service offerings, and accelerate entry of new coagulation-related products into multiple geographies.